Seratrodast - Clinical Experience - Asthma

Asthma

In various clinical studies, seratrodast improved lung function parameters such as FEV1, FVC and PEF, and clinical symptoms of asthma such as wheezing, shortness of breath, cough, expectoration and chest tightness. The improvement in PEF with seratrodast (80 mg o.d. for 28 days) was found to be significantly greater than Montelukast (10 mg o.d. for 28 days). With respect to the levels of various biochemical parameters of sputum, seratrodast showed significant reduction in sputum fucose, eosinophil cationic protein (ECP) and albumin levels. The decrease in sputum ECP and albumin levels with seratrodast was found to be better than Montelukast In a 6-week comparative clinical study with zafirlukast 20 mg, seratrodast was observed to have a better control over asthma compared to zafirlukast (71.68% vs. 62.62%). Seratrodast (80 mg o.d.) administered over 12 weeks was found to decrease airway hyper-responsiveness to acetylcholine with significant improvement in PEF, clinical symptoms of asthma and sputum ECP levels. In a 6-week clinical study with seratrodast (40 mg o.d.), significant decrease in the amount and dynamic viscosity of sputum, and reduction in nasal clearance time of saccharin particle were observed. Long term administration of seratrodast (80 mg o.d.) over 2 years was observed to lessen exacerbation rate of asthma in patient after first 12 months of therapy and reduce the average dose of inhaled beclomethasone dipropionate (iBDP).

Read more about this topic:  Seratrodast, Clinical Experience

Other articles related to "asthma":

Creola Bodies
... Creola bodies are a histopathologic finding indicative of asthma ... columnar cells sloughed from the bronchial mucosa of a patient with asthma ... Other common findings in the sputum of asthma patients include Charcot-Leyden crystals, Curschmann's Spirals, and eosinophils (and excessive amounts of sputum) ...
La Jolla Institute For Allergy And Immunology - Research - OX40 Ligand in Asthma
... A major asthma discovery by a researcher at the Institute has been licensed by MedImmune, a biotechnology company and wholly owned subsidiary of AstraZeneca PLC ... its use in the development of a potential biologics drug for treating asthma ... of a protein called the OX40 ligand in asthma ...
La Jolla Institute For Allergy And Immunology - Research - Allergy and Asthma Research
... Asthma accounts for one-quarter of all emergency room visits in the U.S ... It might come as a surprise to many that asthma results from the good intentions of the body, gone bad ... Asthma can occur when T cells, the body's disease-fighting cells, respond to a stimulus and cause inflammation of the bronchial tubes, making ...
Asthma - History
... Asthma was recognized in Ancient Egypt and was treated by drinking an incense mixture known as kyphi Officially recognized as a specific respiratory problem separate from others was first ... During the 1930s–50s, asthma was considered as being one of the 'holy seven' psychosomatic illnesses ... depression was especially important for individuals with asthma ...